Confident Investing Starts With TipRanks Premium

Get 55% Off
TipRanks
Go Ultimate55% OFF

Corline Biomedical AB (CLBIO) Stock Price & Analysis

CLBIO Stock Chart & Stats

SEK 13.85-SEK 0.35(-2.46%)
At close: 5:24 PM GMT+1
kr 14kr 16kr 1810 Aug24 Aug7 Sep21 Sep5 Oct19 Oct2 Nov
Day’s Range
SEK 13.50 - SEK 14.15
52-Week Range
SEK 13.05 - SEK 20.20
Previous Close
SEK 14.20
Volume
N/A
Average Volume (3M)
7,002
Market Cap
SEK 371.09M
Enterprise Value
SEK 436.10M
Total Cash (Recent Filing)
SEK 32.99M
Total Debt (Recent Filing)
SEK 0
Price to Earnings (P/E)
―
Beta
0.43
Next Earnings
Nov 19, 2026 (Est.)
EPS Estimate
N/A
Next Dividend Ex-Date
N/A
Dividend Yield
N/A

Bulls Say, Bears Say

Bulls Say

Debt-free Balance Sheet

Zero debt removes leverage and refinancing pressure, while the sizable equity base provides resilience against operating volatility. This gives Corline greater flexibility to fund development, absorb losses, and pursue commercial opportunities without the additional burden of mandatory interest or principal payments.

Strong Revenue Growth

Double-digit trailing revenue growth indicates that Corline is gaining commercial traction for its products and technologies. If sustained, expanding revenue can improve operating leverage, support broader customer adoption, and provide a foundation for reducing losses as the business scales.

Specialized Blood-contact Technology

Corline addresses a specialized medical need by improving biocompatibility in blood-contacting procedures and devices. Its applications across transplantation, perfusion, medical devices, and advanced therapies create several routes for product sales, collaborations, and technology adoption.

Bears Say

Persistent Net Losses

Persistent substantial losses show that current revenue has not yet supported a profitable operating model. Continued negative margins can limit internally funded investment, require additional capital over time, and make future earnings dependent on successful commercialization and cost improvement.

Ongoing Cash Burn

Negative operating and free cash flow indicate that Corline is consuming cash rather than financing operations internally. The deterioration in free cash flow increases the importance of improved operating performance or external funding, potentially constraining development and commercial execution.

Volatile Earnings Performance

The shift from profitability to near break-even and then materially larger losses demonstrates limited earnings stability. Such volatility makes the business harder to forecast, reduces confidence in near-term operating leverage, and indicates that revenue growth has not yet translated consistently into durable profits.

CLBIO FAQ

What was Corline Biomedical AB’s price range in the past 12 months?
Corline Biomedical AB lowest stock price was kr 13.05 and its highest was kr 20.20 in the past 12 months.
What is Corline Biomedical AB’s market cap?
Corline Biomedical AB’s market cap is kr 371.09M.
When is Corline Biomedical AB’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Corline Biomedical AB’s earnings last quarter?
Corline Biomedical AB released its earnings results on Aug 21, 2026. The company reported -kr 0.055 earnings per share for the quarter.
Is Corline Biomedical AB overvalued?
Not enough analysts have published a price target to calculate whether the price is overvalued.
Does Corline Biomedical AB pay dividends?
Corline Biomedical AB does not currently pay dividends.
What is Corline Biomedical AB’s EPS estimate?
Corline Biomedical AB’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Corline Biomedical AB have?
Corline Biomedical AB has 26,133,118 shares outstanding.
What happened to Corline Biomedical AB’s price movement after its last earnings report?
Corline Biomedical AB reported an EPS of -kr 0.055 in its last earnings report. Following the earnings report the stock price went up 0.833%.
Which hedge fund is a major shareholder of Corline Biomedical AB?
Currently, no hedge funds are holding shares in SE:CLBIO
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology